Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 14, 2016

Amgen and UCB report positive Phase III BRIDGE study results of romosozumab to treat osteoporosis

Amgen and UCB have reported positive results from its Phase III BRIDGE study of romosozumab for treating men with osteoporosis.

Amgen and UCB have reported positive results from its Phase III BRIDGE study of romosozumab for treating men with osteoporosis.

The placebo-controlled study evaluating the efficacy and safety of romosozumab in treating men with osteoporosis (BRIDGE) study was held as a multicentre, international, randomised, double-blind, placebo-controlled study examining 245 men with osteoporosis.

The patients were randomised to receive a subcutenous administration of romosozumab or placebo for a year and received calcium and vitamin D on a daily basis.

The BRIDGE study is a part of a comprehensive Phase III programme for romosozumab.

"Romosozumab has the ability to improve bone mass, structure and strength by both increasing bone formation and decreasing bone resorption."

Results from the study showed that in males with osteoporosis, romosozumab increased bone mineral density (BMD) at the lumbar spine, total hip and femoral neck in comparison to placebo at six and 12 months.

The study also met its secondary endpoint of romosozumab achieving BMD gains at total hip and the femoral neck at 12 months.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

BRIDGE study principal investigator and University of New Mexico School of Medicine clinical assistant professor of medicine Michael Lewiecki said: "Romosozumab has the ability to improve bone mass, structure and strength by both increasing bone formation and decreasing bone resorption.

"These Phase III findings are particularly promising as they show the clinical effects of romosozumab in men with osteoporosis a population that is often under-recognised and under-treated for a disease that can have devastating consequences."

Romosozumab has been developed as a humanised monoclonal antibody that fuses and inhibits sclerostin, a protein secreted by bone cells that prevents bone formation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU